VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
David F. Stojdl(Ottawa Regional Cancer Foundation), John C. Bell(Ottawa Hospital), Jennifer M Paterson(University of Ottawa), Russell K. Durbin(Nationwide Children's Hospital), John Hiscott(Istituto Pasteur), Laurent Poliquin(Université du Québec à Montréal), Anthony Power(University of Ottawa), Shane Knowles(Ottawa Regional Cancer Foundation), Benjamin R. tenOever(New York University), Jennifer Reynard(Ottawa Regional Cancer Foundation), Ricardo Marius(Ottawa Regional Cancer Foundation), Brian D. Lichty(McMaster University Medical Centre), Joan E. Durbin(New York University), Earl G. Brown(University of Ottawa), Harold Atkins(University of Ottawa)
Cited by 850
Related Papers
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids
|Cell stem cell|2020|676
Hostile takeovers: viral appropriation of the NF-kB pathway
|Journal of Clinical Investigation|2001|606